Steve Bryson, PhD,  science writer—

Amylyx Pharmaceuticals‘ investigational oral therapy AMX0035 reduces the levels of several biomarkers associated with Alzheimer’s disease, according to an analysis of data from the PEGASUS trial. “The results from this exploratory analysis suggest that AMX0035 engages important pathways implicated in the [development] of Alzheimer’s disease and other neurodegenerative…

VY-TAU01, Voyager Therapeutics’s investigational therapy designed to prevent the formation of harmful tau tangles in the brains of people with Alzheimer’s disease, was well tolerated and showed promising pharmacological properties in preclinical studies. Based on these findings, the company expects to submit an application to the U.S. Food…

Enrollment is now complete in the LIFT-AD clinical trial evaluating Athira Pharma‘s fosgonimeton, an experimental treatment for mild-to-moderate Alzheimer’s disease. The Phase 2/3 study (NCT04488419) enrolled about 315 participants, who received either 40 mg fosgonimeton or a placebo for 26 weeks (about six months). Top-line data is expected in…

NE3107, BioVie Pharma’s experimental oral therapy, was superior to a placebo at improving performance of adults with mild-to-moderate Alzheimer’s disease on all cognitive and functional assessments of a Phase 3 clinical trial, top-line efficacy data shows. However, these differences failed to reach statistical significance due to a loss…

Weekly injections of an investigational formulation of the Alzheimer’s disease therapy Leqembi (lecanemab) worked better than the approved treatment in removing harmful amyloid beta plaques from patients’ brains over six months in a Phase 3 trial. In fact, the subcutaneous or under-the-skin formulation cleared 14% more plaques in…

Treatment for two years with oral ALZ-801 (valiltramiprosate) sustained cognition and lowered levels of disease-related biomarkers in people with early Alzheimer’s disease carrying one or two copies of the disease-linked APOE4 genetic variant. These are the top-line findings of an ongoing Phase 2 clinical trial (NCT04693520), whose…

Vaccine candidate UB-311 is safe, well tolerated, and triggered an antibody response against beta-amyloid in 93% of patients with mild Alzheimer’s disease, according to now published data from a Phase 2a trial. Immunization also led to nonsignificant trends in reducing beta-amyloid and slowing cognitive, functional, and dementia decline,…

Recruitment has begun for a Phase 2 clinical trial that’s evaluating Cognition Therapeutics’ once daily oral therapeutic candidate Elayta in adults with early Alzheimer’s disease. START (NCT05531656) expects to enroll about 540 adults, ages 50-85. The University of Kentucky Sanders-Brown Center on Aging (SBCoA) is the first to…

“Encouraging results” were reported in eight Alzheimer’s disease patients with dementia who were treated with COYA 301, an experimental therapy being evaluated in a small clinical trial, according to Coya Therapeutics, its developer. “Results of our open-label proof-of-concept study with COYA 301 in 8 patients with Alzheimer’s showed…

Nearly half of Alzheimer’s disease patients treated with TrueBinding’s investigational therapy TB006 for at least three months showed signs of disease reversal or cognitive improvement, according to data from an open-label extension (OLE) study. The findings expand on data from a completed Phase 2a trial (NCT05074498) that…